Jeff Sperinde

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

Ritwik Ghosh, Archana Narasanna, Shizhen Emily Wang et al. · Cancer Research · 2011 · 223 citations · Full text

Breast Oncology, Her2 Homodimers, Immunology +17

High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

Maurizio Scaltriti, Paolo Nucíforo, Ian Bradbury et al. · Clinical Cancer Research · 2014 · 102 citations · Full text

A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue

Yining Shi, Weidong Huang, Yuping Tan et al. · Diagnostic Molecular Pathology · 2009 · 89 citations

Breast Oncology, Molecular Biology, Pathology +22

Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2

Roni Mamluk, Irvith M. Carvajal, Brent Morse et al. · mAbs · 2010 · 79 citations · Full text

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

Jame Abraham, A.J. Montero, Rachel C. Jankowitz et al. · Journal of Clinical Oncology · 2019 · 79 citations · Full text